You are here:

rilpivirine hydrochloride (Edurant)

Advice

following an abbreviated submission:

rilpivirine (Edurant®) is accepted for use within NHS Scotland.

Indication under review: in combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.

The Scottish Medicines Consortium has previously accepted rilpivirine in this indication in adult patients.

Drug Details

Drug Name: rilpivirine hydrochloride (Edurant)
SMC Drug ID: 1168/16
Manufacturer: Janssen-Cilag Ltd
Indication: In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 8 August 2016

Back